Key Takeaways:
- Interim net profit seen at USD 24-25.4 million, up 69-78.9% YoY
- Revenue forecast at USD 229-231 million, up 41.9-43.1% YoY
- Clear aligner case volume rises ~40% to roughly 316,600 cases
返回
Angelalign forecasts interim profit up to 79% on aligner demand
Angelalign Technology Inc. expects interim net profit of USD 24-25.4 million for the six months ended June 30, up 69-78.9 percent year over year.
Management attributed the growth to rising clinician preference for clinically proven aligners, the payoff from years of investment in global direct sales and localized support infrastructure, and an open multinational innovation culture that is strengthening brand recognition in both overseas and Chinese markets.
Revenue is forecast at USD 229-231 million, up 41.9-43.1 percent year over year, with clear aligner case volume rising about 40 percent to roughly 316,600 cases. The stock opened 8.2 percent higher and peaked at HKD 97, up 21.4 percent, before settling at HKD 93.6, up 17.15 percent, with 1.73 million shares traded for HKD 160 million in turnover.
The profit alert comes as the company's market capitalization stands at HK$13.68 billion. The most recent analyst rating on the stock is a Buy with a HK$91.89 price target, and the technical sentiment signal is Strong Buy.
The company, which provides clear aligner orthodontics to both mainland Chinese and global markets, has been expanding its presence in adolescent and paediatric patient segments. Its model centers on direct sales and localized customer service and clinical support for dental professionals, a strategy that has gained traction as clinicians increasingly favor aligners with published clinical evidence.
The profit alert follows years of investment in direct sales infrastructure and localized clinical support across multiple markets. Angelalign competes with Align Technology's Invisalign brand and Straumann in the global clear aligner market, where demand has been growing steadily across both adult and younger patient cohorts. The company's average daily trading volume stands at roughly 580,844 shares.
The company did not disclose EPS or an interim dividend in the profit alert. Short selling data as of July 31 showed HK$6.91 million in short positions, representing a ratio of 17.04 percent.
The interim results, when released, will provide the first full look at how the company's expansion into overseas markets is translating into profitability. The company has been investing heavily in building direct sales teams and clinical support networks outside China, a strategy that has weighed on margins in prior periods but is now showing signs of paying off.
The guidance points to accelerating demand for clear aligners across both domestic and international markets, with efficiency gains now flowing through to the bottom line. Investors will watch the full interim results for segment-level margins, geographic revenue breakdown, and any interim dividend declaration.
This article is for informational purposes only and does not constitute investment advice.
[1] ANGELALIGN (06699.HK) Once Surges Over 21%; Interim Profit Expected to Jump Nearly 80%[2] Angelalign Technology (06699) issues profit guidance, expecting net profit of approximately USD 24 million to USD 25.4 million for the first half of the year, representing a year-over-year increase of 69.0% to 78.9%.[3] Angelalign forecasts sharp profit and revenue gains on ...
